This article has been updated to correct details regarding SYL1001's development timeline.

Spanish RNAi drug developer Sylentis is gearing up to begin a phase II trial of its investigational glaucoma treatment SYL040012, which could start as soon as by the end of the year, Gene Silencing News has learned.

At the same time, the company plans to begin a second phase I trial of an RNAi-based treatment for dry eye-associated pain, called SYL1001, later this year, according to a Sylentis spokeswoman.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.